All In Biotech

Drug Trial Radar · NCT06554184

HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

A Randomized Phase III Study Evaluating the Efficacy and Safety of HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 706 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

706

Actual

Start

Sep 3, 2024

Primary completion

Jul 28, 2025

Study completion Oct 3, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aimed to evaluate the efficacy and safety of HR20013 versus palonosetron for nausea and vomiting associated with moderate emetic risk anticancer agents

Conditions

  • Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Interventions

  • HR20013 + dexamethasone + palonosetron placeboDrug

    HR20013 + dexamethasone + palonosetron placebo

  • Palonosetron + dexamethasone + HR20013 placeboDrug

    Palonosetron + dexamethasone + HR20013 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rate in the delayed phaseTime frame: 24-120 hours after initiation of moderate emetic risk anticancer agents

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center Yuexiu Campus

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.